NEW YORK (GenomeWeb News) – Shares of Sequenom were up 14 percent in mid-afternoon trade on the Nasdaq after the firm announced earlier today the launch of its SensiGene Fetal (XY) test through its CLIA lab, the Sequenom Center for Molecular Medicine.
The new SensiGene test is a non-invasive assay that detects circulating cell-free fetal DNA in maternal blood. It interrogates male specific targets on the Y chromosome and runs on Sequenom's MassArray system.
Sequenom said that a validation study showed that the test had 97.9 percent sensitivity and 100 percent specificity.
The firm's shares were up $.63 at $5.15 in Tuesday afternoon trade on the Nasdaq.
Two weeks ago, Sequenom's shares spiked on the launch of its SensiGene Fetal RHD Genotyping test.
Sequenom's shares had not traded above $5 since late September 2009. At that time, the firm had announced the dismissal of its CEO and other top executives in the wake of an investigation into the mishandling of test data on its Down Syndrome test.